Pfizer, the firm behind prescription drugs from anxiety medication Zoloft to Viagra, agreed Monday to pay $11.4 billion for Array BioPharma and its cutting-edge treatments for colon and rectal cancers.

The Boulder, Colo.-based target’s portfolio includes the combination of Braftovi and Mektovi, drugs used for skin cancers that spread from one part of the body to another that are now being tested on colorectal tumors in more than two dozen clinical trials.

Recommended Stories

Bristol-Myers buys Celgene for $74 billion amid growing drug-price scrutiny

Pharma industry sales climb despite Trump’s pressure on prices

Despite price hikes, older drugs weigh on Pfizer’s profits